Agilent Technologies fiscal Q2 revenues rise 7%

By Author Proscia | May 25, 2023

According to Michael McMullen, CEO, president, and director of Agilent, the company’s pathology business led to growth for the Diagnostics and Genomics Group.  This includes the introduction of Agilent’s end-to-end digital pathology workflow solution, which is made up of offerings from Proscia, Visiopharm, Hamamatsu, and Agilent, at USCAP.

Our website uses cookies. By using this site, you agree to its use of cookies.